{{Short description|Chemical compound}} {{Drugbox | IUPAC_name = (6''Z'')-6-[butylamino-(2-chlorophenyl)methylene]-4-chloro-cyclohexa-2,4-dien-1-one | image = Fengabine.png | image_class = skin-invert-image | width = 150px
<!--Clinical data--> | tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral
<!--Pharmacokinetic data--> | bioavailability = | metabolism = | elimination_half-life = | excretion =
<!--Identifiers--> | CAS_number = 80018-06-0 | ATC_prefix = none | ATC_suffix = | PubChem = 5362066 | ChemSpiderID = 4514924 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = YQG0NJI5A7 | KEGG = D04149
<!--Chemical data--> | C=17 | H=17 | Cl=2 | N=1 | O=1 }}
'''Fengabine''' ('''SL-79,229''') is a drug which was investigated as an antidepressant but was never marketed.<ref name="pmid3033203">{{cite journal | vauthors = Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G | title = Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 241 | issue = 1 | pages = 245–50 |date=April 1987 | doi = 10.1016/S0022-5347(25)00326-X | pmid = 3033203 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3033203| url-access = subscription }}</ref><ref name="pmid3033204">{{cite journal | vauthors = Scatton B, Lloyd KG, Zivkovic B | title = Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 241 | issue = 1 | pages = 251–7 |date=April 1987 | pmid = 3033204 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3033204|display-authors=etal | doi = 10.1016/S0022-5347(25)00327-1 | url-access = subscription }}</ref> Its mechanism of action is unknown, but its antidepressant effects are reversed by GABA<sub>A</sub> receptor antagonists like bicuculline and it has hence been labeled as GABAergic; however, it does not actually bind to GABA receptors, nor does it inhibit GABA-T.<ref name="pmid3033203"/><ref name="pmid3033204"/> In clinical trials, fengabine's efficacy was comparable to that of the tricyclic antidepressants, but with a more rapid onset of action and much less side effects.<ref name="pmid2668780">{{cite journal | vauthors = Magni G, Garreau M, Orofiamma B, Palminteri R | title = Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics | journal = Neuropsychobiology | volume = 20 | issue = 3 | pages = 126–31 | year = 1989 | pmid = 2668780 | doi = 10.1159/000118485}}</ref><ref name="pmid2281807">{{cite journal | vauthors = Nielsen NP, Cesana B, Zizolfi S, Ascalone V, Priore P, Morselli PL | title = Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine | journal = Acta Psychiatrica Scandinavica | volume = 82 | issue = 5 | pages = 366–71 |date=November 1990 | pmid = 2281807 | doi = 10.1111/j.1600-0447.1990.tb01402.x| s2cid = 44534975 }}</ref><ref name="pmid8471403">{{cite journal | vauthors = Fairweather DB, Kerr JS, Hilton S, Hindmarch I | title = A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers | journal = British Journal of Clinical Pharmacology | volume = 35 | issue = 3 | pages = 278–83 |date=March 1993 | pmid = 8471403 | pmc = 1381575 | doi = 10.1111/j.1365-2125.1993.tb05695.x}}</ref> Notably, fengabine lacks any sedative effects.<ref name="pmid2281807"/>
== See also == * Pivagabine *Tolgabide *Progabide
== References == {{Reflist}}
{{Antidepressants}} {{Anxiolytics}}
Category:Chlorobenzene derivatives Category:Imines Category:Phenols Category:Drugs with unknown mechanisms of action Category:2-Chlorophenyl compounds